Aurobindo Pharma (BOM:524804) Cyclically Adjusted Revenue per Share: ₹507.49 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524804 Aurobindo Pharma Ltd BOM:524804
86 GF Score
Price ₹1,606.40
GF Value ₹1,397.57
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Aurobindo Pharma Cyclically Adjusted Revenue per Share?

Aurobindo Pharma BOM:524804 -0.54% 86 Cyclically Adjusted Revenue per Share is ₹507.49 as of Jun. 2026. GuruFocus rates BOM:524804 with a GF Score™ of 86/100 and a GF Value™ of ₹1,397.57 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Aurobindo Pharma's adjusted revenue per share for the three months ended in Jun. 2026 was ₹157.502. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹507.49 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Aurobindo Pharma's average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Aurobindo Pharma was 11.70% per year. The lowest was 9.10% per year. And the median was 11.10% per year.

As of today (2026-08-21), Aurobindo Pharma's current stock price is ₹1606.40. Aurobindo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹507.49. Aurobindo Pharma's Cyclically Adjusted PS Ratio of today is 3.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aurobindo Pharma was 3.59. The lowest was 1.08. And the median was 2.43.


Aurobindo Pharma  (BOM:524804) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aurobindo Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1606.40/507.49
=3.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aurobindo Pharma was 3.59. The lowest was 1.08. And the median was 2.43.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Aurobindo Pharma Cyclically Adjusted Revenue per Share Related Terms


Aurobindo Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Aurobindo Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma Cyclically Adjusted Revenue per Share Chart

Aurobindo Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 338.64 382.96 425.44 457.54 496.62

Aurobindo Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 468.76 481.05 488.57 496.62 507.49

BOM:524804 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Cyclically Adjusted PS Ratio falls into.


BOM:524804
86GF Score
Aurobindo Pharma Ltd BOM:524804
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurobindo Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aurobindo Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=157.502/167.3573*167.3573
=157.502

Current CPI (Jun. 2026) = 167.3573.

Aurobindo Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 64.832 105.961 102.397
201612 66.702 105.196 106.117
201703 62.238 105.196 99.015
201706 62.789 107.109 98.108
201709 75.697 109.021 116.201
201712 74.041 109.404 113.262
201803 69.105 109.786 105.343
201806 72.570 111.317 109.104
201809 81.118 115.142 117.904
201812 88.287 115.142 128.324
201903 88.754 118.202 125.663
201906 91.411 120.880 126.558
201909 94.176 123.175 127.956
201912 98.980 126.235 131.223
202003 103.495 124.705 138.893
202006 99.258 127.000 130.799
202009 108.795 130.118 139.932
202012 108.419 130.889 138.627
202103 102.276 131.771 129.897
202106 97.135 134.084 121.239
202109 100.477 135.847 123.783
202112 102.212 138.161 123.812
202203 98.880 138.822 119.205
202206 105.372 142.347 123.885
202209 96.859 144.661 112.055
202212 108.967 145.763 125.110
202303 108.803 146.865 123.985
202306 115.884 150.280 129.053
202309 121.165 151.492 133.854
202312 124.567 152.924 136.324
202403 128.287 153.035 140.294
202406 127.293 155.789 136.745
202409 130.963 157.882 138.823
202412 135.875 158.323 143.628
202503 144.344 157.552 153.328
202506 134.154 159.755 140.538
202509 141.838 162.289 146.267
202512 148.120 163.281 151.818
202603 150.662 164.272 153.491
202606 157.502 167.357 157.502

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹507.49 mean?
Aurobindo Pharma (BOM:524804) has a Cyclically Adjusted Revenue per Share of ₹507.49 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aurobindo Pharma and its competitors.
Is Aurobindo Pharma's Cyclically Adjusted Revenue per Share too high?
Aurobindo Pharma's current Cyclically Adjusted Revenue per Share is ₹507.49. Overall, Aurobindo Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Aurobindo Pharma's Cyclically Adjusted Revenue per Share of ₹507.49 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aurobindo Pharma and its competitors. Aurobindo Pharma's current Cyclically Adjusted Revenue per Share is ₹507.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,397.57, compared to a current price of ₹1,606.40 — trading 14.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹507.49. Aurobindo Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current Cyclically Adjusted Revenue per Share is ₹507.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?

Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued. The current stock price of ₹1,606.40 is trading 14.9% above its estimated GF Value™ of ₹1,397.57. GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524804:

  • Cyclically Adjusted Revenue per Share: ₹507.49
  • GF Value™: ₹1,397.57 vs. price of ₹1,606.40 (14.9% above fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurobindo Pharma Business Description

Other Exchanges AUROPHARMA:India
Address Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
86GF Score

Get the complete analysis for BOM:524804

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,606.40
Price
₹1,397.57
GF Value